Callan Family Office LLC Has $5.96 Million Stake in Merck & Co., Inc. $MRK

Callan Family Office LLC grew its holdings in Merck & Co., Inc. (NYSE:MRK) by 232.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 75,305 shares of the company’s stock after purchasing an additional 52,686 shares during the period. Callan Family Office LLC’s holdings in Merck & Co., Inc. were worth $5,961,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the business. Barnes Dennig Private Wealth Management LLC purchased a new stake in shares of Merck & Co., Inc. during the 1st quarter worth about $27,000. Legend Financial Advisors Inc. purchased a new stake in shares of Merck & Co., Inc. during the 2nd quarter worth about $25,000. CBIZ Investment Advisory Services LLC raised its stake in shares of Merck & Co., Inc. by 141.7% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 377 shares of the company’s stock worth $34,000 after purchasing an additional 221 shares in the last quarter. MorganRosel Wealth Management LLC purchased a new stake in shares of Merck & Co., Inc. during the 1st quarter worth about $36,000. Finally, Fiduciary Wealth Partners LLC purchased a new stake in shares of Merck & Co., Inc. during the 1st quarter worth about $48,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Merck & Co., Inc. in a research note on Wednesday. Berenberg Bank downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating and cut their price target for the stock from $100.00 to $90.00 in a research note on Wednesday, September 17th. Morgan Stanley cut their price target on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating for the company in a research note on Thursday, July 10th. Finally, Wells Fargo & Company cut their price target on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $104.31.

Merck & Co., Inc. Stock Performance

Shares of NYSE MRK opened at $86.02 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.17 and a current ratio of 1.42. The firm has a market cap of $214.87 billion, a price-to-earnings ratio of 13.25, a P/E/G ratio of 0.90 and a beta of 0.37. The business’s 50-day simple moving average is $83.47 and its 200-day simple moving average is $81.51. Merck & Co., Inc. has a 52 week low of $73.31 and a 52 week high of $111.58.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $2.13 EPS for the quarter, beating analysts’ consensus estimates of $2.03 by $0.10. The business had revenue of $15.81 billion for the quarter, compared to analyst estimates of $15.92 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. As a group, equities research analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, October 7th. Shareholders of record on Monday, September 15th were issued a $0.81 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.24 dividend on an annualized basis and a yield of 3.8%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 49.92%.

About Merck & Co., Inc.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.